XENE - CIK 0001582313
The table below shows Xenon Pharmaceuticals Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $545.87M | $104.51M | $135.38M | $116.66M | $87.62M | $136.73M |
| Short-term investments | $548.88M | $357.75M | $352.16M | $432.97M | $566.39M | $584.80M |
| Receivables | - | - | - | - | $938.00K | $853.00K |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $1.11B |
| $480.14M |
| $500.25M |
| $565.54M |
| $659.64M |
| $728.09M |
| Property, plant & equipment | $8.29M | $8.89M | $9.21M | $9.70M | $10.16M | $10.14M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.39B | $607.84M | $674.28M | $743.28M | $835.90M | $884.01M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $39.81M | $38.34M | $33.05M | $32.03M | $29.70M | $31.29M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $48.99M | $48.33M | $40.30M | $39.32M | $38.09M | $39.96M |
| Retained earnings | -$1.35B | -$1.14B | -$1.05B | -$964.52M | -$833.78M | -$771.00M |
| Total equity | $1.34B | $559.51M | $633.98M | $703.96M | $797.81M | $844.05M |